Hospitalized patients with primary Sjögren’s syndrome (pSS) show an increased rate of specific cardiovascular concerns and sleep apnea syndrome (SAS), according to a study of a nationwide health insurance database in France. The cardiovascular issues include ischemic heart disease (heart disease associated with narrowed blood vessels) and pulmonary hypertension…
News
No connection is evident between exposure to the dental amalgam used to fill cavities and the risk of developing Sjögren’s syndrome, a study by researchers in Taiwan reported. The study, “Analysis of dental amalgam fillings on primary Sjögren’s syndrome,” was published in Medicine. Dental amalgam is…
A first patient has enrolled in a Phase 3 trial evaluating cenegermin in treating dry eye disease in people with Sjögren’s syndrome, marking the start of a two-part clinical study program, Dompé, the therapy’s developer, announced. The program will evaluate the safety and efficacy of…
Telitacicept (RC18), an experimental therapy being developed by RemeGen, significantly eased disease activity in people with primary Sjögren’s syndrome in a Phase 2 clinical trial, the company announced. “We are very excited to see the positive results from the Phase II clinical trial of telitacicept,” Jianmin Fang,…
Patients with primary Sjögren’s syndrome who experience symptoms such as pain, fatigue, and anxiety are more likely to show a decline in quality of life over time, according to a real-world study from the U.K. The study, “Primary Sjögren’s…
Punctal plugs, which are inserted into the tear ducts to keep the eyes lubricated, are a mainstay of treatment for dry eye in people with primary Sjögren’s syndrome, a South Korean study found. The approach may be combined with additional treatments, but appropriate therapies will depend on the presence…
Combining the anti-inflammatory medicines hydrocortisone and ciclosporin A could help ease eye symptoms in people with Sjögren’s syndrome, according to a new study. The study, “Efficacy of Topical Hydrocortisone in Combination with Topical Ciclosporin A for the Treatment of Dry Eye Disease in Patients with Sjögren…
The experimental oral therapy cenerimod prevented immune cells from entering the salivary glands and reduced gland inflammation in two Sjögren’s syndrome mouse models, a study demonstrated. “These encouraging data suggest that cenerimod may be a promising approach to treating Sjögren’s syndrome,” the scientists said. The study, titled “…
A study has identified concerns common to people with primary Sjögren’s syndrome across five European countries, which researchers hope will help the development of more meaningful patient-reported outcomes and support medical professionals in providing better treatment options. The study, “The Experiences of Functioning and Health of Patients With…
Obstructive sleep apnea (OSA), which occurs when breathing slows or stops repeatedly for short times during sleep, is common among people with primary Sjögren’s syndrome, a study found. Since OSA is associated with an increased risk for cardiovascular problems, fatigue, and other medical problems, physicians should monitor all people with…
Recent Posts
- Sjögren’s disease patients, their relatives face higher cancer risk: Study
- Trio of genes may be new diagnostic markers in Sjögren’s disease: Study
- IMVT-1402 now in global testing, and recruiting adults with Sjögren’s
- Dianthus to develop experimental therapy DNTH212 for Sjögren’s
- Efgartigimod shows signals of benefit in Sjögren’s disease clinical trial
- Sjögren’s symptoms differ by sex, but overall impact similar
- Sjögren’s symptoms extend far beyond dryness, U.S. survey finds
- Study links anti-Ro antibody patterns to disease features in Sjögren’s
- Global trial of telitacicept for Sjögren’s doses first patient ‘within weeks’
- Patients, advocates working this month to raise awareness of Sjögren’s